feed,title,long_url,short_url
Benzinga,Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization,https://benzinga.com/general/biotech/24/10/41189182/johnson-johnson-ends-phase-2-study-for-dengue-antiviral-amid-r-d-reprioritization,https://da.gd/KKNxk8
